See the DrugPatentWatch profile for Tigecycline

Tigecycline for injection is a patented drug used for the treatment of various infections. According to the sources provided, Tigecycline is a broad-spectrum antibiotic that belongs to the glycylcycline class. It is primarily used to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1][2].

The first source, DrugPatentWatch, provides information about the patent status of Tigecycline. It indicates that the patent for Tigecycline expired on June 17, 2020. This suggests that the drug may now be available in generic form, potentially leading to lower costs and increased accessibility for patients [1].

The second source, a research article published in the National Center for Biotechnology Information (NCBI), provides a comprehensive overview of Tigecycline. It highlights the drug's mechanism of action, pharmacokinetics, and clinical efficacy. The article also discusses the various infections that Tigecycline is approved to treat, along with dosage recommendations and potential side effects [2].

The third source, a summary review document from the U.S. Food and Drug Administration (FDA), provides detailed information about the approval process for Tigecycline. It includes data on the drug's safety and effectiveness, as well as the results of clinical trials. The document also provides information on the recommended dosage, administration, and potential drug interactions [3].

In conclusion, Tigecycline for injection is a patented antibiotic used to treat certain types of infections. The patent for Tigecycline expired in 2020, potentially leading to the availability of generic versions of the drug. It is important to consult healthcare professionals and refer to the FDA-approved prescribing information for accurate and up-to-date information on Tigecycline's use and safety [1][2][3].

Sources:
[1] DrugPatentWatch. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE
[2] National Center for Biotechnology Information. (2014). Tigecycline: An Update. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037176/
[3] U.S. Food and Drug Administration. (2016). Tigecycline for Injection, 50 mg and 100 mg. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205645Orig1s000SumR.pdf